|
Synonyms: GAP-134 | ZP-1609 | ZP1609
Compound class:
Synthetic organic
Comment: Danegaptide (GAP-134, and formerly ZP 1609) is an orally bioavailable gap-junction modifier that targets connexin-43. It is the successor molecule to rotigaptide which was intravenously administered. Like rotigaptide, danegaptide was initially intended for the treatment of chronic heart conditions such as ventricular arrhythmias and atrial fibrillation, but focus was diverted to the role of connexin-43 modulation in diabetic retinopathy.
|
|
|||||||||||||||||
| References |
|
1. Hudson N, Porkoláb G, O'Callaghan J, Hanley N, Baccouche B, Varró M, Mouritzen U, Lind BE, Adamson P, Campbell M. (2026)
Preclinical and clinical evaluation of systemic danegaptide for the treatment of nonproliferative diabetic retinopathy. Sci Transl Med, 18 (868): eaed8692. [PMID:42777083] |